Literature DB >> 28213668

Effect of Percutaneous Coronary Intervention on Survival in Patients with Stable Ischemic Heart Disease.

Francisco Ujueta1, Ephraim N Weiss1, Binita Shah1, Steven P Sedlis2.   

Abstract

PURPOSE OF REVIEW: This study aims to determine if percutaneous coronary intervention (PCI) does improve survival in stable ischemic heart disease (SIHD). RECENT
FINDINGS: The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial will evaluate patients with moderate to severe ischemia and will be the largest randomized trial of an initial management strategy of coronary revascularization (percutaneous or surgical) versus optimal medical therapy alone for SIHD. Although the ISCHEMIA trial may show a benefit with upfront coronary revascularization in this high-risk population, cardiac events after PCI are largely caused by plaque rupture in segments outside of the original stented segment. Furthermore, given the robust data from prior randomized trials, which showed no survival benefit with PCI, and the likelihood that the highest risk patients in ISCHEMIA will be treated with surgery, it is unlikely that the ISCHEMIA trial will show a survival benefit particular to PCI. RECENT
FINDINGS: Although PCI relieves symptoms, the evidence base indicates that it does not prolong survival in SIHD.

Entities:  

Keywords:  Coronary artery bypass grafting; Long-term survival; Optimal medical therapy; Percutaneous coronary intervention; Stable ischemic heart disease

Mesh:

Year:  2017        PMID: 28213668     DOI: 10.1007/s11886-017-0821-6

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  48 in total

1.  Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants.

Authors: 
Journal:  Lancet       Date:  1997-08-16       Impact factor: 79.321

2.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.

Authors:  Friedrich W Mohr; Marie-Claude Morice; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; Marie-angèle Morel; Nic Van Dyck; Vicki M Houle; Keith D Dawkins; Patrick W Serruys
Journal:  Lancet       Date:  2013-02-23       Impact factor: 79.321

3.  Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.

Authors:  Kaare H Bønaa; Jan Mannsverk; Rune Wiseth; Lars Aaberge; Yngvar Myreng; Ottar Nygård; Dennis W Nilsen; Nils-Einar Kløw; Michael Uchto; Thor Trovik; Bjørn Bendz; Sindre Stavnes; Reidar Bjørnerheim; Alf-Inge Larsen; Morten Slette; Terje Steigen; Ole J Jakobsen; Øyvind Bleie; Eigil Fossum; Tove A Hanssen; Øystein Dahl-Eriksen; Inger Njølstad; Knut Rasmussen; Tom Wilsgaard; Jan E Nordrehaug
Journal:  N Engl J Med       Date:  2016-08-29       Impact factor: 91.245

Review 4.  Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia.

Authors:  Hemal Gada; Ajay J Kirtane; Dean J Kereiakes; Sripal Bangalore; Jeffrey W Moses; Philippe Généreux; Roxana Mehran; George D Dangas; Martin B Leon; Gregg W Stone
Journal:  Am J Cardiol       Date:  2015-02-12       Impact factor: 2.778

5.  Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-22       Impact factor: 91.245

6.  The final 10-year follow-up results from the BARI randomized trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

7.  Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine.

Authors:  P M Hartigan; J C Giacomini; E D Folland; A F Parisi
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

8.  Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Authors:  Sripal Bangalore; Sunil Kumar; Mario Fusaro; Nicholas Amoroso; Michael J Attubato; Frederick Feit; Deepak L Bhatt; James Slater
Journal:  Circulation       Date:  2012-05-14       Impact factor: 29.690

9.  Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.

Authors:  Eric J Velazquez; Kerry L Lee; Robert H Jones; Hussein R Al-Khalidi; James A Hill; Julio A Panza; Robert E Michler; Robert O Bonow; Torsten Doenst; Mark C Petrie; Jae K Oh; Lilin She; Vanessa L Moore; Patrice Desvigne-Nickens; George Sopko; Jean L Rouleau
Journal:  N Engl J Med       Date:  2016-04-03       Impact factor: 91.245

10.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

View more
  1 in total

1.  Suxiao Jiuxin Pill protects cardiomyocytes against mitochondrial injury and alters gene expression during ischemic injury.

Authors:  Xiaofen Ruan; Tiejun Chen; Xiaolong Wang; Yiping Li
Journal:  Exp Ther Med       Date:  2017-08-18       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.